Literature DB >> 7975861

Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers.

L Cárdenas1, U Dasgupta, J D Clements.   

Abstract

It is now accepted that oral killed typhoid vaccines are not effective at inducing protective anti-typhoid immunity. It is not known whether oral killed Salmonella can function as an effective carrier of other antigens to the immune system. In order to test this hypothesis, we immunized groups of mice with viable and non-viable preparations of aroA Salmonella dublin strain EL23 which codes for production of the binding subunit of the heat-labile enterotoxin of Escherichia coli (LT-B). Animals immunized orally with viable EL23 developed serum and mucosal anti-LT-B responses consistent with our previous findings. Significantly, mice immunized orally with ultraviolet-killed EL23 developed serum and mucosal antibody responses equivalent to those which developed in animals orally immunized with the same number of viable EL23. We extended these observations to include a number of methods of killing the organisms which may also preserve the ability of these strains to function as carriers. Our findings indicate that viability is not a requirement for use of a Salmonella strain as an immunological carrier. Moreover, our evidence indicates that bacteraemia and persistence in tissues are not necessary for oral priming, and therefore it may be best to dissociate the question of what makes the best live oral anti-typhoid vaccine from the question of what makes a good carrier of heterologous antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975861     DOI: 10.1016/0264-410x(94)90293-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Delivery of the p67 sporozoite antigen of Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle.

Authors:  I Gentschev; I Glaser; W Goebel; D J McKeever; A Musoke; V T Heussler
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Mucosal and systemic immune responses to chimeric fimbriae expressed by Salmonella enterica serovar typhimurium vaccine strains.

Authors:  H Chen; D M Schifferli
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C.

Authors:  M Roberts; A Bacon; J Li; S Chatfield
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

4.  The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.

Authors:  J Benyacoub; S Hopkins; A Potts; S Kelly; J P Kraehenbuhl; R Curtiss; P De Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

5.  Candidate live, attenuated Salmonella enterica serotype Typhimurium vaccines with reduced fecal shedding are immunogenic and effective oral vaccines.

Authors:  Moataz Abd El Ghany; Angela Jansen; Simon Clare; Lindsay Hall; Derek Pickard; Robert A Kingsley; Gordon Dougan
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

6.  Genetic control of antibody responses induced against an antigen delivered by recombinant attenuated Salmonella typhimurium.

Authors:  C Fayolle; D O'Callaghan; P Martineau; A Charbit; J M Clément; M Hofnung; C Leclerc
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

7.  Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier.

Authors:  S Barzu; A Fontaine; P Sansonetti; A Phalipon
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

8.  Differential production of interleukin-12 mRNA by murine macrophages in response to viable or killed Salmonella spp.

Authors:  C Chong; K L Bost; J D Clements
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

9.  Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.

Authors:  David Baud; Françoise Ponci; Martine Bobst; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain.

Authors:  H C Guillobel; J I Carinhanha; L Cárdenas; J D Clements; D F de Almeida; L C Ferreira
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.